Results from the trial, which involved 407 postherpetic neuralgia (PHN) patients, did not demonstrate statistically significant efficacy relative to placebo in patients receiving an 1800mg total daily dose
The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent expires in November 2011. “Today’s decision is yet
Pieris is developing a novel class of targeted human protein therapeutics called Anticalins. In studies of its proprietary PRS-060 Anticalin candidate, the company reports that the protein can
The monoclonal antibody, produced by GBI to standards fully compliant with both US and European requirements, will be used to kick off the initial phase of a multicenter
The investigational compound entered Phase I clinical development in 2006 and, although generally well tolerated, was discontinued as the product profile is unsuitable for further development, said Karo
Other preliminary data results included clinical activity confirmed in chemotherapy-induced anemia (CIA), a condition associated with a significant rate (e.g., 40-50%) of non-response to recombinant erythropoietin (rhEPO); and
The agreement provides for an upfront payment, annual license fees, milestone payments and royalties on any product sales. Payments under the agreement to Wyeth could aggregate $5 million
The primary objective of the phase I/II study is to determine the safety and maximum tolerated dose of GRN163L when administered intravenously in combination with a standard paclitaxel/carboplatin
FluMist is a live trivalent virus vaccine that uses an attenuated form of the influenza virus to stimulate a protective immune response in the body. It was approved
Tetracycline antibiotics are used for treating moderate to severe inflammatory acne. Paratek says it has developed novel narrow-spectrum antibacterial tetracyclines with improved anti-inflammatory activity, tolerability and other properties
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.